Key result
Growth hormone therapy effectively restores normal growth in children with growth hormone deficiency and idiopathic short stature, but the validity of growth hormone stimulation tests as the diagnostic gold standard is questionable.
Why the study?
Does recombinant human growth hormone therapy improve height in children with short stature?
Does recombinant human growth hormone therapy improve height in children with short stature?
This is the authors' abstract. We don't add key points for this paper.
hormone therapy was in 1958 when growth hormone extracted from the pituitary gland was first used for growth hormone deficiency patients. However, its use was discontinued in 1985 after it was found to be associated with Creutzfeldt-Jakob disease. 1) After that, recombinant human growth hormone (rhGH) therapy, available since 1985, was approved not only for growth disturbances linked to GHD, but also for short stature associated with other conditions, such as Turner syndrome, Noonan syndrome, Prader-Willi syndrome, short stature homeobox-containing gene deficiency, chronic renal insufficiency and idiopathic short stature (ISS), as well as in children who are small for gestational age (SGA). xperience gained during the last 15-20 years has shown that GH treatment is effective in restoring normal growth in children with GHD and other forms of growth retardation, including ISS and SGA with insufficient catch-up growth. Meta-analysis of results from 21 clinical studies indicated that children with ISS who received rhGH had significantly higher height increment at the end of the first year than the control group, an effect that persisted in the second year of treatment. This treatment also improved final adult height. The difference between the 2 groups was equal to 5.3 cm for male patients and 4.7 cm for female patients. esults from subjects in a large observational study in Korea demonstrated increased height standard deviation score (SDS) from the baseline in subjects with GHD and ISS. oon et al. 5) evaluated growth response to GH treatment for 2 years in patients with GHD and ISS. In addition, the authors sought to evaluate whether there was a difference in the effect of GH therapy according to peak GH on GH stimulation test. They reported no difference in height SDS and height velocity between GHD and ISS patients after treatment with growth hormone for 2 years. Moreover, there was no significant difference in the response to growth hormone treatment according to peak GH among GHD patients.
Answers are grounded in this paper and cite their sources.
Growth hormone therapy effectively improves height in children with short stature, and the clinical utility of GH stimulation tests for diagnosing GHD may be limited.
No takes yet. Share an insight, caveat, or question.
Hae Sang Lee (2022) conducted an editorial in Short stature (Growth hormone deficiency and Idiopathic short stature). Growth hormone therapy was evaluated. Growth hormone therapy effectively restores normal growth in children with growth hormone deficiency and idiopathic short stature, but the validity of growth hormone stimulation tests as the diagnostic gold standard is questionable.
Synapse has enriched 10 related papers. Consider them for comparative context: